Screening of Human M2 Macrophage-Specific Markers for Preparation of Humanized Inflammation-Triggering Engineered Macrophage (MacTrigger)

DOI Web Site 参考文献36件
  • Tanito Kenta
    Graduate School of Systems Life Sciences, Kyushu University, 744 Motooka, Nishi-ku, Fukuoka 819–0395, Japan
  • Nii Teruki
    Graduate School of Systems Life Sciences, Kyushu University, 744 Motooka, Nishi-ku, Fukuoka 819–0395, Japan Department of Applied Chemistry, Faculty of Engineering, Kyushu University, 744 Motooka, Nishi-ku, Fukuoka 819–0395, Japan
  • Kishimura Akihiro
    Graduate School of Systems Life Sciences, Kyushu University, 744 Motooka, Nishi-ku, Fukuoka 819–0395, Japan Department of Applied Chemistry, Faculty of Engineering, Kyushu University, 744 Motooka, Nishi-ku, Fukuoka 819–0395, Japan Center for Future Chemistry, Kyushu University, 744 Motooka, Nishi-ku, Fukuoka 819–0395, Japan Center for Molecular Systems, Kyushu University, 744 Motooka, Nishi-ku, Fukuoka 819–0395, Japan
  • Mori Takeshi
    Graduate School of Systems Life Sciences, Kyushu University, 744 Motooka, Nishi-ku, Fukuoka 819–0395, Japan Department of Applied Chemistry, Faculty of Engineering, Kyushu University, 744 Motooka, Nishi-ku, Fukuoka 819–0395, Japan Center for Future Chemistry, Kyushu University, 744 Motooka, Nishi-ku, Fukuoka 819–0395, Japan
  • Katayama Yoshiki
    Graduate School of Systems Life Sciences, Kyushu University, 744 Motooka, Nishi-ku, Fukuoka 819–0395, Japan Department of Applied Chemistry, Faculty of Engineering, Kyushu University, 744 Motooka, Nishi-ku, Fukuoka 819–0395, Japan Center for Future Chemistry, Kyushu University, 744 Motooka, Nishi-ku, Fukuoka 819–0395, Japan Center for Molecular Systems, Kyushu University, 744 Motooka, Nishi-ku, Fukuoka 819–0395, Japan Center for Advanced Medical Innovation, Kyushu University, 3–1–1 Maidashi, Higashi-ku, Fukuoka 812–8582, Japan Department of Biomedical Engineering, Chung Yuan Christian University, 200 Chung Pei Rd., Chung Li 32023, Taiwan

この論文をさがす

説明

<p>We previously reported the development of inflammation-triggering engineered mouse macrophages (mMacTriggers) that achieve tumor-specific release of tumor necrosis factor-α (TNF-α) in response to the promoter of Arginase 1 (Arg1), an M2-specific marker in murine macrophages. Tumor-specific TNF-α release induced acute inflammation, which recruited natural killer cells or cytotoxic T cells to attack the tumor, leading to significant antitumor effects. This strategy primarily leverages innate immunity-mediated tumor suppression, which is expected to have minimal side effects—an approach noted worldwide. However, we have one issue with preparing human macrophage-derived MacTrigger (hMacTrigger) for clinical application: the Arg1 promoter is unsuitable for human use due to the low expression of Arg1 in human macrophages. Therefore, this study aimed to identify human M2 macrophage-specific markers to replace murine Arg1 through data analysis and quantitative evaluation. From an initial selection of 30 gene candidates by data analysis, we identified 8 genes with high specificity by quantitative evaluation. Among them, 4 genes—arachidonate 15-lipoxygenase (ALOX15), sialic acid-binding immunoglobulin (Ig)-like lectin 10 (SIGLEC10), fatty acid binding protein 4 (FABP4), and C-C motif chemokine ligand 22 (CCL22)—were confirmed as M2-specific markers in human macrophages. Future research will focus on preparing hMacTrigger by constructing vectors encoding TNF-α under the control of each identified gene promoter and evaluating its anti-tumor effects and side effects in vivo. This study represents a critical step toward the clinical application of the MacTrigger strategy and advances its potential use in cancer immunotherapy.</p>

収録刊行物

参考文献 (36)*注記

もっと見る

キーワード

詳細情報 詳細情報について

問題の指摘

ページトップへ